gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 08 Dec 2016.

Inhibitor of Bruton agammaglobulinemia tyrosine kinase

IBtk, Btk-binding protein, inhibitor of Bruton's tyrosine kinase
The protein encoded by this gene binds to Bruton's tyrosine kinase (BTK) and downregulates BTK's kinase activity. In addition, the encoded protein disrupts BTK-mediated calcium mobilization and negatively regulates the activation of nuclear factor-kappa-B-driven transcription. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Btk, CAN, HAD, BCR, V1a
Papers on IBtk
Ibrutinib for mantle cell lymphoma.
New
Rule et al., Plymouth, United Kingdom. In Future Oncol, Feb 2016
Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor.
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.
New
Schetelig et al., Dresden, Germany. In Bone Marrow Transplant, Feb 2016
UNASSIGNED: Ibrutinib, a recently approved inhibitor of Bruton's tyrosine kinase (BTK), has shown great efficacy in patients with high-risk CLL.
Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
New
Takahara et al., Tokyo, Japan. In Int J Hematol, Jan 2016
UNLABELLED: In this phase I dose-escalation study we evaluated the safety, tolerability, pharmacokinetics, and antitumor activity of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK, in Japanese patients with relapsed/refractory B cell malignancies (RRBCM).
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
New
Impact
HELIOS investigators et al., Jacksonville, United States. In Lancet Oncol, Jan 2016
We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Review
New
Wiestner, Bethesda, United States. In Haematologica, Dec 2015
Ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, and idelalisib, a selective inhibitor of PI3Kδ, have obtained regulatory approval in chronic lymphocytic leukemia.
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Review
New
Zhuang et al., United States. In Ann N Y Acad Sci, Nov 2015
Ibrutinib is a first-in-class oral covalent inhibitor of Bruton's tyrosine kinase that has demonstrated clinical benefit for many patients with B cell malignancies.
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
New
Jones et al., Columbus, United States. In Leukemia, Nov 2015
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of relapsed CLL and CLL with del(17p).
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.
Review
New
Spurgeon et al., Salt Lake City, United States. In Ther Adv Hematol, Oct 2015
Ibrutinib is an inhibitor of Bruton's tyrosine kinase, a vital component of this pathway.
Stable isotope-intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
New
de Jong et al., Beerse, Belgium. In Br J Clin Pharmacol, Oct 2015
AIMS: Ibrutinib, an inhibitor of Bruton's tyrosine kinase is used in the treatment of mantle cell lymphoma or chronic lymphocytic leukemia.
Targets for Ibrutinib Beyond B Cell Malignancies.
Review
New
Smith et al., Stockholm, Sweden. In Scand J Immunol, Sep 2015
Ibrutinib (Imbruvica™) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK).
A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.
Review
Rule et al., Plymouth, United Kingdom. In Ther Clin Risk Manag, 2014
Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase, which functions by irreversible inhibition of the downstream signaling pathway of the B-cell receptor, which normally promotes cell survival and proliferation.
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Impact
O'Brien et al., Houston, United States. In Lancet Oncol, 2014
BACKGROUND: Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL).
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Impact
RESONATE Investigators et al., Aş Şanamayn, Syria. In N Engl J Med, 2014
We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.
Ibrutinib treatment of CLL: the cancer fights back.
Impact
Staudt et al., Bethesda, United States. In Cancer Cell, 2014
Ibrutinib is a potent inhibitor of Bruton's tyrosine kinase (BTK).
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Impact
Byrd et al., Ulm, Germany. In N Engl J Med, 2014
BACKGROUND: Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL).
Btk regulation in human and mouse B cells via protein kinase C phosphorylation of IBtkγ.
GeneRIF
Scala et al., Catanzaro, Italy. In Blood, 2011
A novel pathway of Btk regulation via protein kinase C phosphorylation of IBtkgamma.
Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia.
GeneRIF
Vilela et al., Campinas, Brazil. In Braz J Med Biol Res, 2010
three novel (Ala347fsX55, I355T, and Thr324fsX24) mutations in Bruton's tyrosine kinase in patients with X-linked agammaglobulinemia
Computational analysis and in vivo validation of a microRNA encoded by the IBTK gene, a regulator of B-lymphocytes differentiation and survival.
GeneRIF
Quinto et al., Catanzaro, Italy. In Comput Biol Chem, 2009
The IBTK gene encodes the proteins IBtk-alpha, beta and gamma that regulate the B cell receptor signalling through Bruton's tyrosine kinase, which promotes B cell survival and differentiation.
Physical and functional characterization of the genetic locus of IBtk, an inhibitor of Bruton's tyrosine kinase: evidence for three protein isoforms of IBtk.
GeneRIF
Scala et al., Catanzaro, Italy. In Nucleic Acids Res, 2008
Identification of three IBTKalpha, IBTKbeta and IBTKgamma mRNAs, whose transcription is driven by two distinct promoter regions.
share on facebooktweetadd +1mail to friends